Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 52, Issue 15, 2009, Pages 4640-4649

  Zhao, Chen ^a   Sun, Minghua ^a,b   Bennani, Youssef L ^a,c   Miller, Thomas R ^a   Witte, David G ^a   Esbenshade, Timothy A ^a   Wetter, Jill ^a   Marsh, Kennan C ^a   Hancock, Arthur A ^a   Brioni, Jorge D ^a   Cowart, Marlon D ^a  

^a ABBOTT LABORATORIES   (United States)

^b ELAN PHARMACEUTICALS   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4' METHOXYBIPHENYL 4 YL) 5 METHYLOCTAHYDROPYRROLO[3,4 B]PYRROLE; 1 [4' (5 METHYLHEXAHYDROPYRROLO[3,4 B]PYRROL 1 YL)BIPHENYL 4 YL]ETHANONE; 4' (5 METHYLHEXAHYDROPYRROLO[3,4 B]PYRROL 1 YL)BIPHENYL 4 CARBONITRILE; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; 5 METHYLOCTAHYDROPYRROLO[3,4 B]PYRROLE; BENZO[4,5]HYDRINDENO[1,7 AC] 1 BENZYLPYRROLIDINE DERIVATIVE; BENZOFURAN DERIVATIVE; CONESSINE; G PROTEIN COUPLED RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; PYRROLE DERIVATIVE; PYRROLIDINE DERIVATIVE; PYRROLO[3,4 B]PYRROLE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; ISOTOPE LABELING; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HISTAMINE H3 ANTAGONISTS; HUMANS; PYRROLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68549132508     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900480x     Document Type: Article

References (30)

1. 3) of histamine receptor. Nature 1983, 302, 832-837.
2. 3 receptor. Mol. Pharmacol. 1999, 55, 1101-1107.
3. 3 Heteroreceptors. Fundam. Clin. Pharmacol. 1994, 8, 128-137.
4. 3 receptors regulates histamine neurons in brain. Nature 2000, 408, 860-864.
5. (c) Brown, R. E.; Stevens, D. R.; Haas, H. L. The physiology of brain histamine. Prog. Neurobiol. 2001, 63 (6), 637-672.
6. 3 receptor agonists and antagonists. Trends Pharmacol. Sci. 1998, 19, 177-183.
7. 3 receptor antagonists. Drugs Future 1996, 21, 507-520.
8. 3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interventions 2006, 6 (2), 77-88.
9. 3 receptor: an attractive target for the treatment of cognitive disorders. Br. J. Pharmacol. 2008, 154 (6), 1166-1181.
10. 3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 2007, 321 (3), 1032-1045.
11. Monti, J. M. Involvement of histamine in the control of the waking state. Life Sci. 1993, 53, 1331-1338.
12. Oades, R. D. Attention deficit disorder with hyperactivity (ADDH): The contribution of catecholaminergic activity. Prog. Neurobiol. 1987, 29 (4), 365-391.
13. Velligan, D. I.; Miller, A. L. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J. Clin. Psychiatry 1999, 60, 25-28.
14. (a) Ulrici, F. Conessine. Arch Pharm. 1918, 256, 57-80.
15. (b) Giemsa, G.; Halberkann, J. Conessine. Arch. Pharm. 1918, 256, 201-222.
16. (c) McNiven, N. L. Some simple 18-oxygenated steroids: the constitution of conessine. Chem. Ind. 1957, 1296-1297.
17. 3 Receptor Antagonists. J. Med. Chem. 2008, 51 (17), 5423-5430.
18. Kopach, M. E.; Fray, A. H.; Meyers, A. I. An Asymmetric Route to the Conanine BCDE Ring System. A Formal Total Synthesis of (+)-Conessine. J. Am. Chem. Soc. 1996, 118, 9876-9883.
19. 3 Receptor Antagonists Potently Enhance Cognition and Attention. J. Med. Chem. 2005, 48 (1), 38-55.
20. 3 antagonists: 2-aminoethylbenzofurans. Bioorg. Med. Chem. Lett. 2004, 14 (3), 689-693.
21. (a) Li, Q.; Chu, D. T. W.; Claiborne, A.; Cooper, C. S.; Lee, C. M.; Raye, K.; Berst, K. B.; Donner, P.; Wang, W.; Hasvold, L.; Fung, A.; Ma, Z.; Tufano, M.; Flamm, R.; Shen, L. L.; Baranowski, J.; Nilius, A.; Alder, J.; Meulbroek, J.; Marsh, K.; Crowell, D.; Hui, Y.; Seif, L.; Melcher, L. M.; Henry, R.; Spanton, S.; Faghih, R.; Klein, L. L.; Tanaka, S. K.; Plattner, J. J. Synthesis and Structure-Activity Relationships of 2-Pyridones: A Novel Series of Potent DNA Gyrase Inhibitors as Antibacterial Agents. J. Med. Chem. 1996, 39 (16), 3070-3088.
22. (b) (3aR,6aR)-Hexahydro-pyrrolo[3,4-b] pyrrole-1-carboxylic acid tert-butyl ester (18, CAS no. 370880-09-4) may be prepared as described in Basha, A.; Bunnelle, W. H.; Dart, M. J.;Gallagher, M. E.; Ji, J.; Li, T.; Pace, J. M.; Ryther, K. B.; Tietje, K. R.; Mortell, K. H.; Nersesian, D. L.; Schrimpf, M. R. Substituted diazabicycloalkane derivatives. U.S. Pat. Appl. Publ. 2005101602A1, 2005.
23. 3 receptor for the treatment of neurological disorders. PCT Int. Appl. WO2004056369A1, 2004.
24. 3-antagonist receptor activity - A new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg. Med. Chem. Lett. 2006, 16 (15), 5303-5308.
25. Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J. P. Keynote review: Histamine H3 receptor antagonists reach out for the clinic. Drug Discovery Today 2005, 10 (23/24), 1613-1627.
26. (a) Schwink, L.; Stengelin, S.; Gossel, M.; Hessler, G.; Lennig, P. Preparation of 2,7-diazabicyclo[3.3.0]octanes and related compounds as antiobesity agents. PCT Int. Appl. WO2006018280A2, 2006.
27. (b) Schoenafinger, K.; Jaehne, G.; Defossa, E.; Schwink, L.; Wagner, H.; Buning, C.; Tschank, G.; Werner, U. Preparation of substituted bicyclic 8-pyrrolidino-xanthines and use thereof as inhibitors of the dipeptidyl peptidase IV. PCT Int. Appl. WO 2006015699 A1, 2006.
28. Schrimpf, M. R.; Tietje, K. R.; Toupence, R. B.; Ji, J.; Basha, A.; Bunnelle, W. H.;Daanen, J. F.; Pace, J. M.; Sippy, K. B. Preparation of diazabicyclic compounds as central nervous system active agents. PCT Int. Appl. WO 2001081347A2, 2001.
29. (a) Ji, J.; Schrimpf, M. R.; Sippy, K. B.; Bunnelle, W. H.; Li, T.; Anderson, D. J.; Faltynek, C.; Surowy, C. S.; Dyhring, T.; Ahring, P. K.; Meyer, M. D. Synthesis and Structure - Activity Relationship Studies of 3,6-Diazabicyclo[3.2.0]heptanes as Novel α4β2 Nicotinic Acetylcholine Receptor Selective Agonists. J. Med. Chem. 2007, 50 (22), 5493-5508.
30. (b) Schrimpf, M. R.; Sippy, K. B.; Ji, J.; Li, T.; Frost, J. M.; Briggs, C. A.; Bunnelle, W. H. Preparation of amino-substituted tricyclic derivatives as modulators of alpha7 nicotinic receptors and methods of use. U.S. Pat. Appl. Publ. 2005234031A1, 2005.